A new HNE LHD Guideline for antibiotic use in cystic  fibrosis lung disease is now available.  The new guideline covers the microbiology and treatment of common infections in cystic fibrosis patients. Detailed therapeutic advice for commonly used antimicrobials is included.

As many will know, antimicrobial susceptibility testing of pseudomonas and related species in CF sputum are prone to error and are not correlated with clinical response.  This guideline focuses on protocol driven therapy that does not take in to account measured susceptibilities.  Nebulised administration is also favoured.

The guideline is available here.

Picture credit: Pseudomonas sp. from  http://organicsoiltechnology.com/pseudomonas-fluorescens-phosphate-solubilization.html